ATE452190T1 - Verfahren zur isolierung und reinigung von g-csf - Google Patents

Verfahren zur isolierung und reinigung von g-csf

Info

Publication number
ATE452190T1
ATE452190T1 AT95119327T AT95119327T ATE452190T1 AT E452190 T1 ATE452190 T1 AT E452190T1 AT 95119327 T AT95119327 T AT 95119327T AT 95119327 T AT95119327 T AT 95119327T AT E452190 T1 ATE452190 T1 AT E452190T1
Authority
AT
Austria
Prior art keywords
csf
genetically engineered
isolation
purification
animals
Prior art date
Application number
AT95119327T
Other languages
English (en)
Inventor
Thomas C Boone
Allan L Miller
Jeffrey W Andresen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE452190T1 publication Critical patent/ATE452190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
AT95119327T 1988-05-13 1989-05-12 Verfahren zur isolierung und reinigung von g-csf ATE452190T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19385788A 1988-05-13 1988-05-13
US34801189A 1989-05-09 1989-05-09

Publications (1)

Publication Number Publication Date
ATE452190T1 true ATE452190T1 (de) 2010-01-15

Family

ID=26889429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95119327T ATE452190T1 (de) 1988-05-13 1989-05-12 Verfahren zur isolierung und reinigung von g-csf

Country Status (12)

Country Link
US (1) US5849883A (de)
EP (2) EP0347041A3 (de)
JP (1) JP2796388B2 (de)
KR (1) KR0133561B1 (de)
AT (1) ATE452190T1 (de)
AU (3) AU636127B2 (de)
DE (1) DE68929566D1 (de)
DK (1) DK175245B1 (de)
FI (1) FI900178A0 (de)
NO (1) NO300217B1 (de)
NZ (1) NZ229098A (de)
WO (1) WO1989010932A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
FI900178A0 (fi) 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH10505232A (ja) * 1994-08-19 1998-05-26 エンブレクス，インコーポレイテッド 鳥類骨髄単球性成長因子を用いる鳥類の処置方法
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ATE260674T1 (de) * 1998-08-17 2004-03-15 Pfizer Prod Inc Stabilisierte proteinzusammensetzung
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
AU2001290846B2 (en) * 2000-09-08 2006-02-02 Massachusetts Institute Of Technology G-CSF analog compositions and methods
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
SI21102A (sl) * 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
EP1490402A4 (de) 2002-03-20 2007-05-02 Biopolymed Inc Herstellung von am cysteinrest stöchiometrisch mit biokompatiblen polymeren konjugiertem g-csf
AU2002345829A1 (en) * 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
WO2005025593A2 (en) * 2003-05-09 2005-03-24 Schering Aktiengesellschaft Treatment of inflammatory respiratory diseases
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
AU2005295043A1 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
EP3000826A1 (de) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Motive der bauchspeicheldrüsen-polypeptid familie, polypeptide und methoden unter verwendung derselben
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US7381805B2 (en) 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
DK2197919T3 (da) 2007-08-27 2014-07-07 Ratiopharm Gmbh Flydende formulering af g-csf-konjugat
CN102089319B (zh) 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
KR101741859B1 (ko) 2009-06-22 2017-06-15 암젠 인크 화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
SI3660032T1 (sl) 2009-06-25 2026-02-27 Amgen Inc. Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu
EP2477643A1 (de) 2009-09-18 2012-07-25 Novo Nordisk A/S V2-rezeptoragonisten mit langzeitwirkung
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
WO2011113601A1 (en) 2010-03-17 2011-09-22 Biogenerix Ag Method for obtaining biologically active recombinant human g-csf
RU2487885C2 (ru) * 2010-07-20 2013-07-20 Зао "Биокад" Способ крупномасштабного получения, выделения и очистки рекомбинантного гранулоцитарного колониестимулирующего фактора человека
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
EP2855517A1 (de) 2012-05-29 2015-04-08 Novo Nordisk A/S Bauchspeicheldrüsenpolypeptidverbindungen und verwendung
WO2014155349A2 (en) 2013-03-29 2014-10-02 Dr. Reddy's Laboratories Refolding of proteins
MX2020003742A (es) * 2017-10-11 2020-10-28 Elanco Us Inc Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos.
WO2020234742A1 (en) * 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
WO2021007243A1 (en) * 2019-07-09 2021-01-14 Tanvex Biopharma Usa, Inc. Temperature-controlled purification of granulocyte-colony stimulating factor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2438821A1 (fr) * 1978-10-13 1980-05-09 France Etat Dispositif d'allumage a fil chaud de securite
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
JPS6145010A (ja) * 1984-08-08 1986-03-04 Setsuji Umezaki 埋立地の造成方法
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4721420A (en) * 1985-09-03 1988-01-26 Arthur D. Little, Inc. Pipeline transportation of coarse coal-liquid carbon dioxide slurry
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
AU626008B2 (en) * 1987-10-23 1992-07-23 Schering Corporation Method of purifying protein
FI900178A0 (fi) 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.

Also Published As

Publication number Publication date
FI900178A7 (fi) 1990-01-12
AU4197293A (en) 1993-10-28
WO1989010932A1 (en) 1989-11-16
EP0347041A3 (de) 1990-11-22
NO300217B1 (no) 1997-04-28
EP0347041A2 (de) 1989-12-20
AU4781290A (en) 1990-11-15
JPH02504521A (ja) 1990-12-20
NZ229098A (en) 1992-10-28
AU4197393A (en) 1993-10-28
US5849883A (en) 1998-12-15
NO900185L (no) 1990-03-12
DE68929566D1 (de) 2010-01-28
AU661172B2 (en) 1995-07-13
EP0719860A1 (de) 1996-07-03
FI900178A0 (fi) 1990-01-12
DK9290D0 (da) 1990-01-12
DK175245B1 (da) 2004-07-19
KR900701824A (ko) 1990-12-04
AU636127B2 (en) 1993-04-22
JP2796388B2 (ja) 1998-09-10
DK9290A (da) 1990-03-09
NO900185D0 (no) 1990-01-12
KR0133561B1 (ko) 1998-04-21
EP0719860B1 (de) 2009-12-16

Similar Documents

Publication Publication Date Title
DE68929566D1 (de) Verfahren zur Isolierung und Reinigung von G-CSF
ES8507535A1 (es) Acidos 7-amino-1-ciclopropil-6,8-difluor-1,4-dihidro-4-oxo-quinolincarboxilicos
MY101842A (en) Treatment of oral diseases.
AU563748B2 (en) Quinolone carboxylic acids
MY130047A (en) Methods and compositions employing certain lysozymes and endoglycosidases
AU579595B2 (en) Enzyme-resistant immunomodulatory peptides
DK16890A (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
EP0308020A3 (de) 5-(Aryl und Heteroaryl)-6-(Aryl und Heteroaryl)-1,2-dihydro-2-oxo-3-pyridincarbonsäure und Derivate davon
DE3869054D1 (de) Polypeptid-wachstumsfaktor aus milch.
ATE120795T1 (de) Ärztliche antimikrobielle polypeptide, deren verwendung und verfahren zur herstellung.
PT88590A (pt) Process for preparing an inactivated vaccine composition
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
SE8803071D0 (sv) Bakteriebehandling for att bevara hokvalitet genom att tillegga genius bacillus mikroorganismer
ATE92717T1 (de) Verfahren zur verbesserung der wirksamkeit von insektentoxinen.
AU2696584A (en) Pharmaceutical compositions of anti-pancreatic inflammatory effect
GB9723945D0 (en) Tissue cement
ATE210989T1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
DE69827163D1 (de) Phytase zur vorbeugung oder behandlung von mastitis
ZA871140B (en) Synergistic chemical compositions for treating salmonellosis
NZ222855A (en) Bacterial composition used as an animal treatment
FI880801A7 (fi) Puun käsittelyyn tarkoitetut koostumukset ja menetelmät puun käsittelemiseksi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties